> ## Content Index > Fetch the complete content index at: https://brief.aiexecutive.media/llms.txt > Use this file to discover other available public pages before exploring further. # Why Is AI Governance in Healthcare Moving From Approval to Continuous Assurance? - URL: https://brief.aiexecutive.media/ai-governance-healthcare-continuous-assurance/ - Published: 2026-09-10T12:00:14.000Z - Updated: 2026-09-10T12:00:14.000Z - Description: Healthcare has moved beyond the first AI governance question — whether a system is safe enough to deploy. The emerging executive requirement is to demonstrate that AI remains safe, controlled, and economically valuable after deployment - Author: AI Executive Media - Tags: Healthcare ## Approval was the old governance endpoint. Continuous assurance is the new one — and it is becoming a performance-management discipline, not a compliance function. Half of surveyed US healthcare organizations have implemented generative AI, yet only 45% of implementers have quantified a return. Deloitte's enterprise survey exposes a wider gap still: 74% of companies plan to deploy agentic AI within two years, while just 21% report a mature governance model for autonomous agents. Adoption is running ahead of both measurable value and control maturity. This issue synthesises intelligence from seven advisory institutions: BCG, McKinsey, Deloitte, EY, PwC, Accenture, and KPMG. The convergence is unusually tight. Every firm extends governance past the deployment gate into ongoing testing, monitoring, and performance management. BCG's 10-20-70 principle puts the point bluntly — 10% of AI transformation impact comes from algorithms, 20% from technology infrastructure, and 70% from operational and organizational redesign. The reframing that matters most for capital allocation is this: governance and deployment speed are not opposed. BCG reports that standardized, pre-governed deployment routes can compress governed agent setup from weeks to roughly a day — an order-of-magnitude gain. The emerging advantage is not less governance. It is reusable governance. For CEOs and boards, that moves AI oversight out of the policy domain and into performance management, capital allocation, and enterprise control. ![](https://storage.ghost.io/c/9d/d9/9dd98c19-d560-46f0-9a4d-b76395086bef/content/images/2026/09/AI_Governance_Evolution_Infographic-1.png) Key Findings at a Glance 50% of surveyed US healthcare leaders have now implemented generative AI McKinsey 45% of implementers have actually quantified their return on investment McKinsey 74% / 21% plan to deploy agentic AI within two years — but only one in five report mature agent governance Deloitte 70% of AI transformation impact comes from operational and organizational redesign, not algorithms BCG ## Table of Contents 1. [Technology Potential & Capabilities](#section-1) Moving from one-time model approval to repeatable controls embedded in the route to production. 2. [Human Resources & Skills Development](#section-2) Why AI value depends on redesigning roles around judgment, supervision, and exception management. 3. [Business Model Transformation](#section-3) How governance becomes part of the operating model — decision rights, delegation, and ownership. 4. [Investment & Return on Investment](#section-4) Why boards need to measure value and trust on the same dashboard. 5. [Industry Applications](#section-5) Applying graduated assurance across clinical, administrative, revenue-cycle, and privacy workflows. 6. [Cross-Article Strategic Synthesis](#cross-article-synthesis) Where the seven firms converge — and the three tensions that divide them. --- Perspective 1 ## Technology Potential & Capabilities *Build continuous AI assurance into production, not around it.* Key Term **Continuous AI Assurance** — The ongoing process of testing, monitoring, validating, and controlling an AI system throughout its operating life, not only before deployment. It covers performance drift, security, data use, human oversight, audit trails, exceptions, and business outcomes. 10x faster governed agent deployment — from weeks to roughly a day — via standardized control routes BCG 74% of companies plan to deploy agentic AI within two years Deloitte 21% report a mature governance model for autonomous agents Deloitte Strategic Core The architecture of AI governance is shifting from approval gates toward embedded runtime control. [BCG](https://www.bcg.com/publications/2026/how-cios-govern-ai-agents-at-scale?ref=brief.aiexecutive.media) recommends an enterprise control layer that standardizes identity, registration, monitoring, policy enforcement, and intervention across AI agents and platforms. Governance is designed into the route to production rather than added as a final checkpoint. [Deloitte](https://www.deloitte.com/us/en/about/press-room/deloitte-expands-end-to-end-ai-controls-and-assurance-capabilities.html?ref=brief.aiexecutive.media) reaches a similar conclusion from an assurance perspective: controls should extend across the AI lifecycle, from initial experimentation through enterprise deployment. Its own survey data explains the urgency — 74% of companies plan to deploy agentic AI within two years, while only 21% report a mature governance model for autonomous agents. For executives, the technology decision is not only about selecting AI tools. It is whether the organization has a repeatable control and assurance environment for the AI systems it scales into production. Strategic Insights A core business argument is speed and productivity. [BCG](https://www.bcg.com/publications/2026/how-cios-govern-ai-agents-at-scale?ref=brief.aiexecutive.media) describes standardized, pre-governed deployment routes that can reduce governed setup from weeks to roughly a day — an improvement it characterizes as on the order of 10x. Centralized governance, on this reading, accelerates teams rather than slowing them. BCG's framework implies that governance performance should be measured through control, visibility, ownership, cost, and deployment speed — not only technical model performance. Management should track deployment cycle time, exception rate, policy violations, model drift, QA pass rate, incident volume, time-to-remediation, and the percentage of AI assets with named ownership. Executive Takeaways - Institutionalize a governed production path so compliance becomes the easiest route to deployment, not a manual hurdle. - Treat AI assurance as an enterprise capability spanning AI risk assessment, model validation, controls, testing, internal audit, and third-party assurance across the AI lifecycle. --- Perspective 2 ## Human Resources & Skills Development *Redesign roles around oversight and exceptions.* Key Term **Human-AI Operating Model** — A definition of how work, judgment, authority, and accountability are divided between employees and AI. It clarifies what AI executes, what humans review, which exceptions escalate, and who remains responsible for the final outcome. 33% reduction in thyroid ultrasound time at RadNet, with over 90% of reads accepted without further review BCG +22% increase in breast cancer detection after radiology was redesigned as a hybrid AI-human system BCG 10-20-70 share of AI impact from algorithms, technology infrastructure, and organizational redesign BCG Strategic Core Healthcare AI is becoming a workforce redesign issue as much as a technology issue. [BCG](https://www.bcg.com/assets/2026/executive-perspectives-ai-first-companies-health-care-providers.pdf?ref=brief.aiexecutive.media) estimates that only 10% of AI transformation impact comes from algorithms and 20% from technology infrastructure; 70% depends on operational and organizational redesign. That includes redefining roles, decision rights, incentives, skills, and end-to-end workflow. [Accenture](https://www.accenture.com/us-en/insights/ai-data/compliance-confidence-responsible-ai-maturity?ref=brief.aiexecutive.media) similarly treats responsible AI as an organizational capability rather than a policy document — combining governance, risk assessment, systematic testing, purchasing standards, employee training, quality assurance, and post-deployment monitoring. The workforce requirement is not simply "AI literacy." Employees need capabilities in AI oversight, exception handling, orchestration, quality, and hybrid AI-human decision-making. Strategic Insights A healthcare case documented by [BCG](https://www.bcg.com/assets/2026/executive-perspectives-ai-first-companies-health-care-providers.pdf?ref=brief.aiexecutive.media) illustrates the economic logic. RadNet rearchitected radiology as a hybrid AI-human production system. The reported results included a 33% decrease in time for thyroid ultrasounds, more than 90% of reads accepted without further review, and a 22% increase in breast cancer detection. Workforce roles shifted toward oversight, orchestration, quality, and exception handling. [Accenture](https://www.accenture.com/us-en/insights/ai-data/compliance-confidence-responsible-ai-maturity?ref=brief.aiexecutive.media) also highlights the maturity gap: in its responsible AI research, 78% of companies have built a responsible AI program, but only 14% have put responsible AI into practice — and no organization yet qualifies as a responsible AI pioneer. The evidence suggests that employee access alone is not enough; organizations need the capabilities to operationalize AI responsibly. A critical capability is the organization's ability to redesign work while embedding clear accountability for AI use. Executive Takeaways - Redesign roles and workflows together; measure capacity, quality, productivity, and human workload alongside AI adoption. - Make AI-risk training role-specific, with deeper requirements for employees who develop, approve, procure, or supervise consequential AI. --- Perspective 3 ## Business Model Transformation *Make governance part of how the business actually runs.* Key Term **Accountability Architecture** — The operating structure that specifies who owns AI-enabled decisions, which actions can be delegated, what limits apply, when humans must intervene, and how performance is reported. 50% of surveyed healthcare leaders have implemented generative AI McKinsey 45% of implementers have quantified their return — the highest share since the survey began McKinsey 30-60% potential reduction in cost to collect from AI-enabled revenue cycle operations McKinsey Strategic Core The consulting consensus is moving away from AI as a collection of productivity tools. [PwC](https://www.pwc.com/us/en/services/ai/ai-transformation-concentrated-bets.html?ref=brief.aiexecutive.media) argues that sustainable value comes from concentrating effort on high-value domains and redesigning the workflows within them, rather than spreading AI thinly across every function where a task could be automated. [McKinsey](https://www.mckinsey.com/industries/healthcare/our-insights/agentic-ai-and-the-race-to-a-touchless-revenue-cycle?ref=brief.aiexecutive.media) reaches a similar conclusion in healthcare. It recommends focusing effort within a single high-value area — revenue cycle being the leading candidate — and rewiring it end to end instead of accumulating disconnected point solutions. This makes governance part of the business operating model, defining accountability, decision rights, delegation boundaries, escalation paths, and controls as AI scales. Strategic Insights [McKinsey](https://www.mckinsey.com/industries/healthcare/our-insights/generative-ai-in-healthcare-current-trends-and-future-outlook?ref=brief.aiexecutive.media) found that 50% of surveyed healthcare leaders had implemented generative AI, while 82% expect a positive return and only 45% have quantified one. Its healthcare research points executives toward process-level indicators: in revenue cycle management, cost to collect, initial denial rates, denial write-off rates, denial overturn rates, accounts receivable days, and time to complete tasks adjusted for complexity. [PwC](https://www.pwc.com/us/en/tech-effect/ai-analytics/ai-predictions.html?ref=brief.aiexecutive.media) adds a governance-by-design layer. It recommends setting concrete business outcomes and "hard" metrics before deployment, articulating explicit steps for human initiative, review, and oversight within each new agentic workflow, and building continuous monitoring in from the start — including agents checking each other's work, drawn from different model providers in higher-risk scenarios. Taken together, PwC and McKinsey imply two management tests for AI-enabled workflows: Is accountability and control clear? Is the workflow delivering measurable business value? Executive Takeaways - Give each priority AI domain business-owned KPIs and empower product owners to remove barriers, stop work, or pivot when performance falls short. - Define delegation boundaries, escalation paths, risk tiers, and performance measures when redesigning AI-enabled workflows — not after go-live. --- Perspective 4 ## Investment & Return on Investment *Measure value and trust on the same dashboard.* Key Term **Value-and-Trust Measurement** — Tracking the financial and operating benefits of an AI system alongside the evidence that it remains controlled. Value metrics can include productivity, cycle time, cost-to-serve, quality, and revenue impact. Trust metrics can include errors, drift, privacy events, security incidents, exceptions, and control effectiveness. 5.8% / 1.8% projected US health expenditure growth versus GDP growth through 2033 BCG 44% / 27% projected hospital wage inflation versus Medicare reimbursement growth, 2025-2033 BCG 33% / 6% error-reduction gains for organizations that can produce AI audit evidence efficiently, versus those that cannot KPMG Strategic Core AI governance should be treated as a value accelerator, not simply as a control or compliance function. [KPMG](https://kpmg.com/au/en/insights/artificial-intelligence-ai/ai-roi-measurement.html?ref=brief.aiexecutive.media) recommends measuring value and trust together, scoping ROI by use case and implementation phase and testing whether value is actually realised as AI moves from pilot to scale. Sustained value, on its argument, depends on trust: governance, controls, and monitoring are what make safe scaling possible. Its [2026 Global AI in Finance Report](https://kpmg.com/xx/en/our-insights/ai-and-technology/kpmg-global-ai-in-finance-report.html?ref=brief.aiexecutive.media) puts numbers behind the claim. Organizations that can produce AI audit evidence efficiently report three to six times the rate of significant improvement compared with those that cannot — 33% versus 6% on error reduction, and 42% versus 14% on confidence in scaling. Assurance readiness proves a stronger predictor of performance than KPI tracking alone. A material AI use case should therefore be assessed on demonstrated value as well as trust and control. Strong value performance should be evaluated alongside trust metrics and control effectiveness before further scaling. Strategic Insights The financial pressure makes disciplined measurement especially relevant in healthcare. [BCG](https://www.bcg.com/assets/2026/executive-perspectives-ai-first-companies-health-care-providers.pdf?ref=brief.aiexecutive.media) projects US health expenditure growth of 5.8% against GDP growth of 1.8% through 2033, while hospital wage inflation is projected to compound at 44% versus 27% reimbursement growth over the same period. With labor at 50-70% of provider cost structures and no pricing power to absorb the gap, productivity becomes the primary available lever. That makes AI performance a question of capacity, cost, quality, and unit economics. The useful metrics are operational and economic: capacity unlocked, cost per episode, manual hours reduced, utilization, throughput, quality improvement, downstream errors, and revenue impact. BCG's own guidance to providers closes the loop — define success metrics upfront, track adoption and economic impact alongside technical performance, and sunset initiatives that fail to deliver sustained value. Executive Takeaways - Measure value and trust together for every material AI use case, pairing business-performance metrics with trust and control indicators. - Prioritize AI investments against workflow economics and capacity constraints, then monitor whether operational gains persist after deployment. --- Perspective 5 ## Industry Applications *Healthcare needs governance at the point where decisions are made.* Key Term **Healthcare AI Governance** — The set of business, clinical, privacy, security, and assurance controls used to manage AI across patient care and administrative workflows. It includes ownership, data use, vendor risk, validation, monitoring, documentation, human intervention, and incident escalation. 72% of healthcare organizations report moderate-to-severe financial impact from cyber incidents EY-KLAS 60% report operational disruption from those same incidents EY-KLAS 50-70% of provider cost structure is labor, split across clinical and administrative work BCG Strategic Core Healthcare's regulatory and data environment makes assurance particularly consequential. [EY](https://www.ey.com/en%5Fus/insights/forensic-integrity-services/healthcare-payer-privacy-governance-in-the-ai-era?ref=brief.aiexecutive.media) argues that payer privacy teams can no longer operate primarily through manual controls, point solutions, and after-the-fact reviews. Privacy and AI oversight need to become part of the operating model, with defined decision authority, traceability, escalation paths, and the ability to halt high-risk activity when thresholds are crossed. [BCG](https://www.bcg.com/assets/2026/executive-perspectives-ai-first-companies-health-care-providers.pdf?ref=brief.aiexecutive.media) applies the same lifecycle principle to providers. Its centralized responsible AI model for healthcare includes named executive and clinical ownership for every AI system, vendor and partner standards, role-based access controls, validation against real-world data before production release, and continuous monitoring for model drift, bias, and safety signals. The through-line is that controls must sit where consequential decisions are actually made — not in a quarterly review cycle downstream of them. Strategic Insights The issue extends well beyond clinical models. AI now affects prior authorization, claims, revenue cycle operations, patient navigation, scheduling, documentation, risk detection, and decision support. [EY](https://www.ey.com/en%5Fus/insights/forensic-integrity-services/healthcare-payer-privacy-governance-in-the-ai-era?ref=brief.aiexecutive.media) cites survey evidence that 72% of healthcare organizations experienced moderate-to-severe financial impact from cyber incidents and 60% experienced operational disruption, reinforcing the cost of fragmented data and control environments. For providers, [BCG](https://www.bcg.com/assets/2026/executive-perspectives-ai-first-companies-health-care-providers.pdf?ref=brief.aiexecutive.media) identifies measurable value pools across scheduling, eligibility, documentation, billing, care navigation, clinical productivity, and revenue integrity — each with different consequence profiles. Governance should therefore maintain baseline controls across all healthcare AI use cases, with enhanced clinician review and escalation reserved for high-risk decisions. Executive Takeaways - Give privacy leaders explicit authority to shape AI-enabled workflow design and escalate or halt high-risk use cases when defined thresholds are exceeded. - Apply centralized responsible AI controls to all use cases, with clinician review for high-risk decisions, pre-production validation, and continuous monitoring of drift, bias, and safety signals. --- Synthesis ## Cross-Article Strategic Synthesis *Where seven advisory firms agree on continuous assurance — and where they pull apart.* #### Strategic Consensus Map Four points of structural agreement across the research: - **Approval is no longer an adequate governance endpoint.** BCG, Deloitte, EY, PwC, Accenture, and KPMG all extend AI governance beyond deployment into ongoing testing, monitoring, assurance, or performance management. The common implementation logic runs: inventory → risk-tier → validate → deploy → monitor → escalate → remediate or retire. - **Business ownership is becoming as important as technical ownership.** McKinsey pushes responsibility toward business-owned domains with measurable outcomes. BCG calls for named executive and clinical owners. PwC defines governance around decision rights and delegation. EY adds explicit escalation authority. "IT owns AI" is becoming an insufficient governance model. - **Governance and deployment speed are not inherently opposed.** The most important reframing comes from BCG: standardized controls can reduce the cost and cycle time of compliant deployment. The emerging advantage is not less governance — it is reusable governance. - **Value realization must become part of AI governance.** McKinsey highlights the gap between AI implementation and quantified return. KPMG goes further, pairing value metrics with trust and control evidence. Boards should expect the AI equivalent of an asset-performance review: what is deployed, what it costs, what it produces, what risk it carries, and whether it deserves more capital. #### Strategic Tensions Where the firms diverge, and what that divergence means for executive decision-making: - **"Centralized control plane" vs "federated ownership."** BCG emphasizes a centralized enterprise control plane because fragmented platform-level governance creates duplicate effort and inconsistent standards. EY emphasizes shared ownership embedded inside business and operational teams, supported by centralized standards. These are complementary rather than exclusive: common standards, identity, inventory, and monitoring centrally; accountability and operational decision-making close to the workflows where risk arises. - **"Build the control environment first" vs "learn while scaling."** BCG presents a relatively structured enterprise architecture. McKinsey places more emphasis on selecting priority domains and learning through business transformation. The practical synthesis is to establish minimum enterprise guardrails early, then industrialize controls around real production workloads rather than waiting for a perfect governance system. - **"Risk reduction" vs "value creation."** Deloitte and EY naturally emphasize assurance, regulatory exposure, privacy, and control. BCG and PwC place stronger emphasis on governance as a source of speed and competitive advantage. For boards, both matter: a governance model focused only on risk reduction can create friction and slow innovation if controls are not designed to support scalable delivery. #### Business Insights for Executives What the consensus and the tensions mean for each constituency: - **Healthcare providers.** Prioritize assurance where AI affects clinical decisions, patient routing, documentation, revenue integrity, or capacity. Monitor throughput, QA pass rate, clinical overrides, cycle time, and drift — not simply user adoption. - **Healthcare payers.** AI governance increasingly overlaps with privacy, prior authorization, fraud, claims, and member communications. Decision rights and data governance need to extend across vendors and automated workflows. - **Life sciences.** The emerging control-plane model is particularly relevant as agentic AI spreads across research, clinical development, regulatory work, and enterprise operations. Identity, permissions, audit trails, and runtime policy enforcement become material controls. - **Boards and investors.** The strategic signal is broader than healthcare. AI governance is starting to resemble a management system for a new class of enterprise assets. The organizations that institutionalize inventory, ownership, performance monitoring, and intervention may be able to scale AI faster while retaining confidence in outcomes. #### The Executive Agenda For organizations still at an exploratory stage, the priority is not the most elaborate governance framework. It is a minimum system that can scale. Five management questions define it: - **Visibility.** Do we know every material AI system operating in the enterprise? - **Ownership.** Is there a named business owner for each consequential use case? - **Evidence.** What must an AI system prove before deployment? - **Performance.** Which value and trust metrics are monitored after go-live? - **Intervention.** Who can restrict, remediate, or retire an AI system when performance deteriorates? --- ## Executive Reflection Closing Thought AI governance is moving from permission to performance management. The objective is no longer to approve AI responsibly once — it is to build an organization capable of proving continuously which AI systems deserve to scale. If the board requested evidence tomorrow that your most important AI systems remain both controlled and economically valuable, how quickly could management produce it? ## Sources & References Primary sources 1. BCG — "Executive Perspectives — Health Care: AI-First Providers Win the Future · Apr 2026" [https://www.bcg.com/assets/2026/executive-perspectives-ai-first-companies-health-care-providers.pdf](https://www.bcg.com/assets/2026/executive-perspectives-ai-first-companies-health-care-providers.pdf?ref=brief.aiexecutive.media) 2. BCG — "Enterprise AI Control Plane: The CIO's Guide to Governing and Accelerating AI Agents · 2026" [https://www.bcg.com/publications/2026/how-cios-govern-ai-agents-at-scale](https://www.bcg.com/publications/2026/how-cios-govern-ai-agents-at-scale?ref=brief.aiexecutive.media) 3. McKinsey & Company — "Generative AI in Healthcare: Adoption Matures as Agentic AI Emerges · Apr 16, 2026" [https://www.mckinsey.com/industries/healthcare/our-insights/generative-ai-in-healthcare-current-trends-and-future-outlook](https://www.mckinsey.com/industries/healthcare/our-insights/generative-ai-in-healthcare-current-trends-and-future-outlook?ref=brief.aiexecutive.media) 4. McKinsey & Company — "Agentic AI and the Race to a Touchless Revenue Cycle · Jan 9, 2026" [https://www.mckinsey.com/industries/healthcare/our-insights/agentic-ai-and-the-race-to-a-touchless-revenue-cycle](https://www.mckinsey.com/industries/healthcare/our-insights/agentic-ai-and-the-race-to-a-touchless-revenue-cycle?ref=brief.aiexecutive.media) 5. Deloitte — "Deloitte Expands End-to-End AI Controls and Assurance Capabilities · Aug 12, 2026" [https://www.deloitte.com/us/en/about/press-room/deloitte-expands-end-to-end-ai-controls-and-assurance-capabilities.html](https://www.deloitte.com/us/en/about/press-room/deloitte-expands-end-to-end-ai-controls-and-assurance-capabilities.html?ref=brief.aiexecutive.media) 6. Deloitte AI Institute — "State of AI in the Enterprise 2026: The Untapped Edge · Jan 2026" [https://www.deloitte.com/us/en/about/press-room/state-of-ai-report-2026.html](https://www.deloitte.com/us/en/about/press-room/state-of-ai-report-2026.html?ref=brief.aiexecutive.media) 7. EY — "Healthcare Payer Privacy Governance in the AI Era · 2026" [https://www.ey.com/en\_us/insights/forensic-integrity-services/healthcare-payer-privacy-governance-in-the-ai-era](https://www.ey.com/en%5Fus/insights/forensic-integrity-services/healthcare-payer-privacy-governance-in-the-ai-era?ref=brief.aiexecutive.media) 8. PwC — "2026 AI Business Predictions" [https://www.pwc.com/us/en/tech-effect/ai-analytics/ai-predictions.html](https://www.pwc.com/us/en/tech-effect/ai-analytics/ai-predictions.html?ref=brief.aiexecutive.media) 9. PwC — "AI Transformation: Why Focused Bets Outperform" [https://www.pwc.com/us/en/services/ai/ai-transformation-concentrated-bets.html](https://www.pwc.com/us/en/services/ai/ai-transformation-concentrated-bets.html?ref=brief.aiexecutive.media) 10. KPMG — "AI ROI Measurement for Scalable Value, Trust and Performance · May 2026" [https://kpmg.com/au/en/insights/artificial-intelligence-ai/ai-roi-measurement.html](https://kpmg.com/au/en/insights/artificial-intelligence-ai/ai-roi-measurement.html?ref=brief.aiexecutive.media) 11. KPMG — "2026 Global AI in Finance Report" [https://kpmg.com/xx/en/our-insights/ai-and-technology/kpmg-global-ai-in-finance-report.html](https://kpmg.com/xx/en/our-insights/ai-and-technology/kpmg-global-ai-in-finance-report.html?ref=brief.aiexecutive.media) 12. Accenture — "Rethinking Responsible AI: From Readiness to Value" [https://www.accenture.com/us-en/insights/ai-data/compliance-confidence-responsible-ai-maturity](https://www.accenture.com/us-en/insights/ai-data/compliance-confidence-responsible-ai-maturity?ref=brief.aiexecutive.media) Supplementary sources 1. Deloitte Insights — "Business and IT Leaders Report AI Agents Are Scaling Faster Than Their Guardrails · Jun 2026" [https://www.deloitte.com/us/en/insights/topics/emerging-technologies/ai-agents-scaling-faster.html](https://www.deloitte.com/us/en/insights/topics/emerging-technologies/ai-agents-scaling-faster.html?ref=brief.aiexecutive.media) 2. EY & KLAS Research — "US Healthcare Cyber Resilience Survey · Nov 3, 2025" [https://www.ey.com/en\_us/newsroom/2025/11/ey-us-klas-healthcare-cybersecurity-survey-reveals-cyber-capability-enablement-a-top-business-priority](https://www.ey.com/en%5Fus/newsroom/2025/11/ey-us-klas-healthcare-cybersecurity-survey-reveals-cyber-capability-enablement-a-top-business-priority?ref=brief.aiexecutive.media) 3. KPMG — "AI Governance for the Agentic AI Era" [https://kpmg.com/us/en/articles/2025/ai-governance-for-the-agentic-ai-era.html](https://kpmg.com/us/en/articles/2025/ai-governance-for-the-agentic-ai-era.html?ref=brief.aiexecutive.media) 4. Accenture — "Accenture and AWS Collaborate to Help Organizations Scale Adoption of AI Responsibly · Aug 2024" [https://newsroom.accenture.com/news/2024/accenture-and-aws-collaborate-to-help-organizations-scale-adoption-of-ai-responsibly](https://newsroom.accenture.com/news/2024/accenture-and-aws-collaborate-to-help-organizations-scale-adoption-of-ai-responsibly?ref=brief.aiexecutive.media) [↑ Back to top](#top) [Table of Contents](#table-of-contents) Follow us: [LinkedIn](https://www.linkedin.com/company/aiexecutive?ref=brief.aiexecutive.media) · [X / Twitter](https://x.com/aiexecutive%5F?ref=brief.aiexecutive.media) **COPYRIGHT & FAIR USE / FAIR DEALING NOTICE** This publication presents original synthesis and commentary based on publicly available research. References to third-party materials are used solely for purposes of analysis, commentary, and reporting, in accordance with Canadian fair dealing, U.S. fair use, and European right of quotation. All trademarks and publications are the property of their respective owners. **EDITORIAL RESPONSIBILITY DISCLAIMER** This newsletter provides interpretive analysis and is not a replacement for the original studies issued by referenced organizations. Readers seeking full methodology, datasets, or detailed results should consult the original publications. © 2026 AI Executive Media · aiexecutive.media